» Articles » PMID: 28334989

Impaired Fetal Muscle Development and JAK-STAT Activation Mark Disease Onset and Progression in a Mouse Model for Merosin-deficient Congenital Muscular Dystrophy

Overview
Journal Hum Mol Genet
Date 2017 Mar 24
PMID 28334989
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Merosin-deficient congenital muscular dystrophy type 1A (MDC1A) is a dramatic neuromuscular disease in which crippling muscle weakness is evident from birth. Here, we use the dyW mouse model for human MDC1A to trace the onset of the disease during development in utero. We find that myotomal and primary myogenesis proceed normally in homozygous dyW-/- embryos. Fetal dyW-/- muscles display the same number of myofibers as wildtype (WT) muscles, but by E18.5 dyW-/- muscles are significantly smaller and muscle size is not recovered post-natally. These results suggest that fetal dyW-/- myofibers fail to grow at the same rate as WT myofibers. Consistent with this hypothesis between E17.5 and E18.5 dyW-/- muscles display a dramatic drop in the number of Pax7- and myogenin-positive cells relative to WT muscles, suggesting that dyW-/- muscles fail to generate enough muscle cells to sustain fetal myofiber growth. Gene expression analysis of dyW-/- E17.5 muscles identified a significant increase in the expression of the JAK-STAT target gene Pim1 and muscles from 2-day and 3-week old dyW-/- mice demonstrate a dramatic increase in pSTAT3 relative to WT muscles. Interestingly, myotubes lacking integrin α7β1, a laminin-receptor, also show a significant increase in pSTAT3 levels compared with WT myotubes, indicating that α7β1 can act as a negative regulator of STAT3 activity. Our data reveal for the first time that dyW-/- mice exhibit a myogenesis defect already in utero. We propose that overactivation of JAK-STAT signaling is part of the mechanism underlying disease onset and progression in dyW-/- mice.

Citing Articles

Laminin-α2 chain deficiency in skeletal muscle causes dysregulation of multiple cellular mechanisms.

Martins S, Ribeiro V, Melo C, Paulino-Cavaco C, Antonini D, Naidu S Life Sci Alliance. 2024; 7(12).

PMID: 39379105 PMC: 11463332. DOI: 10.26508/lsa.202402829.


Effects of Tofacitinib on Muscle Remodeling in Experimental Rheumatoid Sarcopenia.

Bermejo-Alvarez I, Perez-Baos S, Gratal P, Medina J, Largo R, Herrero-Beaumont G Int J Mol Sci. 2023; 24(17).

PMID: 37685986 PMC: 10487422. DOI: 10.3390/ijms241713181.


PAX7, a Key for Myogenesis Modulation in Muscular Dystrophies through Multiple Signaling Pathways: A Systematic Review.

Rahman N, Lam C, Sulaiman N, Abdullah N, Nordin F, Zainal Ariffin S Int J Mol Sci. 2023; 24(17).

PMID: 37685856 PMC: 10487808. DOI: 10.3390/ijms241713051.


Vemurafenib improves muscle histopathology in a mouse model of LAMA2-related congenital muscular dystrophy.

Oliveira-Santos A, Dagda M, Wittmann J, Smalley R, Burkin D Dis Model Mech. 2023; 16(6).

PMID: 37021539 PMC: 10184677. DOI: 10.1242/dmm.049916.


Extracellular matrix: Brick and mortar in the skeletal muscle stem cell niche.

Schuler S, Liu Y, Dumontier S, Grandbois M, Le Moal E, Cornelison D Front Cell Dev Biol. 2022; 10:1056523.

PMID: 36523505 PMC: 9745096. DOI: 10.3389/fcell.2022.1056523.


References
1.
Rossi G, Antonini S, Bonfanti C, Monteverde S, Vezzali C, Tajbakhsh S . Nfix Regulates Temporal Progression of Muscle Regeneration through Modulation of Myostatin Expression. Cell Rep. 2016; 14(9):2238-2249. PMC: 4793149. DOI: 10.1016/j.celrep.2016.02.014. View

2.
Patton B, Miner J, Chiu A, Sanes J . Distribution and function of laminins in the neuromuscular system of developing, adult, and mutant mice. J Cell Biol. 1998; 139(6):1507-21. PMC: 2132624. DOI: 10.1083/jcb.139.6.1507. View

3.
Kuang S, Gillespie M, Rudnicki M . Niche regulation of muscle satellite cell self-renewal and differentiation. Cell Stem Cell. 2008; 2(1):22-31. DOI: 10.1016/j.stem.2007.12.012. View

4.
Copp A, Carvalho R, Wallace A, Sorokin L, Sasaki T, Greene N . Regional differences in the expression of laminin isoforms during mouse neural tube development. Matrix Biol. 2011; 30(4):301-9. PMC: 3565558. DOI: 10.1016/j.matbio.2011.04.001. View

5.
Rooney J, Knapp J, Hodges B, Wuebbles R, Burkin D . Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophy. Am J Pathol. 2012; 180(4):1593-602. PMC: 3349899. DOI: 10.1016/j.ajpath.2011.12.019. View